DE602004019653D1 - Eine Missbrauch verhinderende, transdermale Dosierungsform, die einen Wirkstoff und einen Antagonisten des Wirkstoffs enthält - Google Patents

Eine Missbrauch verhinderende, transdermale Dosierungsform, die einen Wirkstoff und einen Antagonisten des Wirkstoffs enthält

Info

Publication number
DE602004019653D1
DE602004019653D1 DE602004019653T DE602004019653T DE602004019653D1 DE 602004019653 D1 DE602004019653 D1 DE 602004019653D1 DE 602004019653 T DE602004019653 T DE 602004019653T DE 602004019653 T DE602004019653 T DE 602004019653T DE 602004019653 D1 DE602004019653 D1 DE 602004019653D1
Authority
DE
Germany
Prior art keywords
drug
dosage form
agent component
adverse
barrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004019653T
Other languages
German (de)
English (en)
Inventor
John R Hart
Steven C Anderson
Melissa A Vanblaricom
Ellen R Bosl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of DE602004019653D1 publication Critical patent/DE602004019653D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004019653T 2003-04-30 2004-03-23 Eine Missbrauch verhinderende, transdermale Dosierungsform, die einen Wirkstoff und einen Antagonisten des Wirkstoffs enthält Expired - Lifetime DE602004019653D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46724303P 2003-04-30 2003-04-30
US10/744,966 US20040219195A1 (en) 2003-04-30 2003-12-23 Abuse-resistant transdermal dosage form
PCT/US2004/008856 WO2004098568A2 (en) 2003-04-30 2004-03-23 Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer

Publications (1)

Publication Number Publication Date
DE602004019653D1 true DE602004019653D1 (de) 2009-04-09

Family

ID=33313652

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004019653T Expired - Lifetime DE602004019653D1 (de) 2003-04-30 2004-03-23 Eine Missbrauch verhinderende, transdermale Dosierungsform, die einen Wirkstoff und einen Antagonisten des Wirkstoffs enthält

Country Status (9)

Country Link
US (2) US20040219195A1 (enExample)
EP (1) EP1651196B1 (enExample)
JP (2) JP2006525315A (enExample)
AT (1) ATE423551T1 (enExample)
AU (2) AU2004237579A1 (enExample)
CA (1) CA2523709A1 (enExample)
DE (1) DE602004019653D1 (enExample)
ES (1) ES2322154T3 (enExample)
WO (1) WO2004098568A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542969A (en) 2003-04-30 2009-09-25 Purdue Pharma Lp Tamper resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8608889B2 (en) * 2005-06-10 2013-12-17 3M Innovative Properties Company Method for handling adhesive laminate sections
CN101330903B (zh) * 2005-12-13 2015-07-08 生物递送科学国际公司 防滥用的经黏膜给药装置
US7740879B2 (en) * 2006-01-17 2010-06-22 Harrogate Holdings Abuse resistant transdermal drug delivery patch
DE102006025282A1 (de) 2006-05-31 2007-12-20 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System
CN103550136B (zh) 2006-07-21 2016-04-13 生物递送科学国际公司 吸收增强的经粘膜递送装置
US20080140024A1 (en) * 2006-12-08 2008-06-12 Yoseph Yaacobi Drug delivery device
EP2259780A2 (en) * 2008-02-28 2010-12-15 Syntropharma Limited Pharmaceutical composition comprising naltrexone
JP5386205B2 (ja) * 2009-03-19 2014-01-15 リンテック株式会社 経皮吸収型貼付剤
EP3195858B1 (en) * 2010-04-03 2019-08-07 Praful Doshi Medical devices including medicaments and methods of making and using same
ES2660116T3 (es) 2011-08-18 2018-03-20 Biodelivery Sciences International, Inc. Dispositivos mucoadhesivos resistentes al uso inadecuado para la administración de buprenorfina
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
KR102086441B1 (ko) * 2012-03-30 2020-03-09 쓰리엠 이노베이티브 프로퍼티즈 컴파니 우레아계 및 우레탄계 감압 접착제 블렌드
US9950106B2 (en) 2012-12-05 2018-04-24 Cook Medical Technologies Llc Antimicrobial barrier device
LT3096746T (lt) 2014-01-22 2019-06-10 4P Therapeutics Transderminės sistemos, leidžiančios išvengti piktnaudžiavimo vaistais ir netinkamo vaistų vartojimo
CN107107598B (zh) 2014-12-18 2019-11-22 3M创新有限公司 处理粘合层合物贴剂的方法
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
AU2016209190A1 (en) 2015-01-23 2017-08-10 Marcio Marc Abreu Apparatus and method for skin treatment
CN110470607B (zh) * 2018-05-09 2021-12-07 江苏集萃智能液晶科技有限公司 一种检测混合溶液中亲水性有机溶剂含量的方法
WO2020008370A1 (en) * 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal patch

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1602344A (en) * 1924-01-09 1926-10-05 Eagle Peter Medicating compress
US2807262A (en) * 1952-12-10 1957-09-24 Robert B Lew Perforated plastic adhesive tape bandage
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4539256A (en) * 1982-09-09 1985-09-03 Minnesota Mining And Manufacturing Co. Microporous sheet material, method of making and articles made therewith
US4693776A (en) * 1985-05-16 1987-09-15 Minnesota Mining And Manufacturing Company Macromer reinforced pressure sensitive skin adhesive
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US4743249A (en) * 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US4917688A (en) * 1987-01-14 1990-04-17 Nelson Research & Development Co. Bandage for transdermal delivery of systemically-active drug
JPH0538010Y2 (enExample) * 1987-03-17 1993-09-27
DE3722775A1 (de) * 1987-07-09 1989-01-19 Lohmann Therapie Syst Lts Transdermales therapeutisches system
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5176917A (en) * 1989-03-15 1993-01-05 Lts Lohmann Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5756117A (en) * 1992-04-08 1998-05-26 International Medical Asscociates, Inc. Multidose transdermal drug delivery system
JP3592715B2 (ja) * 1993-10-29 2004-11-24 ミネソタ マイニング アンド マニュファクチャリング カンパニー 微細構造化面を有する感圧接着剤
US5494680A (en) * 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
WO1997004835A1 (de) * 1995-07-28 1997-02-13 Novartis Ag Transdermales system
US5840327A (en) * 1995-08-21 1998-11-24 Alza Corporation Transdermal drug delivery device having enhanced adhesion
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US20020110585A1 (en) * 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
NZ528148A (en) * 2001-03-16 2006-02-24 Alza Corp Transdermal patch for administering fentanyl
DE60230138D1 (de) * 2001-05-01 2009-01-15 Euro Celtique Sa Vor missbrauch geschützte opioid-haltige transdermale systeme
DE60336394D1 (de) * 2002-04-23 2011-04-28 Durect Corp Transdermale analgetische systeme mit reduziertem missbrauchspotential
JP4642467B2 (ja) * 2002-08-20 2011-03-02 ユーロ−セルティーク エス．エイ． 活性剤及び塩並びに副作用物質の遊離塩基形を含む経皮剤形
US20040109886A1 (en) * 2002-08-27 2004-06-10 Larry Rigby Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent
US20040191301A1 (en) * 2003-03-27 2004-09-30 Van Duren Albert Philip Transdermal device having a phase change material
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
NZ542969A (en) * 2003-04-30 2009-09-25 Purdue Pharma Lp Tamper resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
DE102004038179A1 (de) * 2004-08-06 2006-03-16 Daimlerchrysler Ag Verfahren zur Herstellung einer thermisch beschichteten Zylinderlauffläche mit einer Einfuhrfase

Also Published As

Publication number Publication date
US20100068249A1 (en) 2010-03-18
ATE423551T1 (de) 2009-03-15
WO2004098568A2 (en) 2004-11-18
AU2010257440B2 (en) 2011-11-24
US20040219195A1 (en) 2004-11-04
CA2523709A1 (en) 2004-11-18
JP2006525315A (ja) 2006-11-09
ES2322154T3 (es) 2009-06-17
AU2004237579A1 (en) 2004-11-18
EP1651196B1 (en) 2009-02-25
JP2012140453A (ja) 2012-07-26
WO2004098568A3 (en) 2005-02-03
AU2010257440A1 (en) 2011-01-20
EP1651196A2 (en) 2006-05-03

Similar Documents

Publication Publication Date Title
DE602004019653D1 (de) Eine Missbrauch verhinderende, transdermale Dosierungsform, die einen Wirkstoff und einen Antagonisten des Wirkstoffs enthält
CY1109070T1 (el) Διαδερμικη μορφη δοσολογιας περιλαμβανουσα ενα δραστικο παραγοντα και ενα αλας και μια μορφη ελευθερης βασεως ενος ανταγωνιστη
EA200501702A1 (ru) Устойчивая к манипуляциям дозировочная форма для трансдермального введения
DE60127277D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
DK2062573T3 (da) Misbrugsresistent opioid indeholdende transdermale systemer
ATE430579T1 (de) Transdermale botulinum-toxin-enthaltende verbindungen
DE602004028841D1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
DK1526839T3 (da) Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
DK1178783T3 (da) Indretning og anvendelse til forögelse af den transdermale permeation af lægemidler
CY1107752T1 (el) Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης
ATE392892T1 (de) Missbrauchssichere transdermale opioid- verabreichungsvorrichtungen
DE602004032149D1 (de) Oros-push-stick für die kontrollierte abgabe von wirkstoffen
JP2006525315A5 (enExample)
RU2004103746A (ru) Фармацевтическая композиция для лечения интерстициального цистита
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
BR0311903A (pt) Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
AR038858A1 (es) Combinacion
NO20062234L (no) Transdemisk,farmasoytisk spray-formulering omfattende en VP/UA kopolymer og en ikke-vandig vehikkel
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
WO2005117871A3 (en) Pharmaceutical compositions for the treatment of pruritus
Cao et al. Efficacy of a topical proteinase-activated receptor-2 inhibitor on cowhage-induced pruritus: a randomized placebo-controlled double-blind study.
DE602004029993D1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition